Generic ‘Skinny Labels’ Get Reprieve As Court Agrees To Rehear Teva/GSK Case
Executive Summary
Federal Circuit panel to reconsider whether Teva induced infringement of GSK Coreg patent despite label carve-out. Biologics and biosimilars could be particularly hurt if ruling stands given FDA’s recent guidance requiring reference to branded product.
You may also be interested in...
AAM Steps Into GSK-Teva Case To Defend Carve-Outs
The AAM has stepped into controversial litigation between Teva and GSK over generic labelling carve-outs, urging the US Court of Appeals for the Federal Circuit to rehear the case to prevent the rules on so-called skinny labels from being subverted.
Latest Vascepa Lawsuit Plunges Hikma Into Induced Infringement Battle
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.
FDA Offers Clarity On Biosimilar Interchangeability
A draft guidance document opened for comment by the FDA offers additional Q&As on issues around biosimilar applications and interchangeability.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: